Diligence memo · auto-generated · as of July 2, 2026
Kairos Pharma, LTD.
Kairos Pharma, LTD. looks over-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Kairos Pharma, LTD. operates in Pharmaceuticals, based in LOS ANGELES.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Kairos Pharma, LTD. has raised $4.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.5M on 2025-01-16.
Most recent recorded round closed around 2025-01-16.
Valuation (modeled)modeled
Provath models Kairos Pharma, LTD. at approximately $13M (range $2.6M–$29M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.05× the median modeled value of Seed Pharmaceuticals companies in 2025–2027 (19 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 31 months.
Last raise 17 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 5.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 39% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 21% of those peers.
Closest niche peers: Branch Therapeutics, Inc., ResBiotic Nutrition, Inc., Califia Pharma, Inc., BTB Therapeutics, Inc., Avana Health, Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.